BECTON DICKINSON & CO
BDXLatest QuantConomy context for BDX: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
BECTON DICKINSON & CO
Becton Dickinson & Co (BDX) is an American multinational medical technology company that specializes in the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. The company operates through three main business segments: BD Medical, which offers consulting and analytics services to healthcare providers; BD Life Sciences, which includes biosciences, integrated diagnostic solutions, and lab automation; and BD Interventional, known for its line of medical devices such as needles, syringes, and sharps-disposal units. Founded in 1897 by Maxwell Becton and Fairleigh S. Dickinson, BD is a leading global player in the healthcare industry, with a significant presence in international markets and a strong commitment to environmental and social responsibility. The company is listed on the New York Stock Exchange and has a long history of paying quarterly dividends to its shareholders.
- Symbol
- BDX
- Name
- BECTON DICKINSON & CO
- Coverage
- 3 market/data records
- Sources
- alphavantage fmp alpaca sec nasdaq lse
Recent signals for BDX
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| new position | bullish | 69 | Jul 3, 05:38 PM | CONFLUENCE INVESTMENT MANAGEMENT LLC initiated new position in 0A8033 ($13.60M) - 89,902 shares ($13.60M) - [strong bullish signal] |
| earnings release | neutral | 40 | Feb 9, 12:00 AM | BDX filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-09. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| increased position | very bullish | 73 | Jun 23, 07:24 AM | Woodline Partners LP increased position in 0A8033 by 126.6% - 260,446 shares ($50.54M) - [strong very bullish signal] |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
INSTITUTIONAL signals are experimental: historical 13F coverage is still being backfilled, so results may be sparse or empty.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| BDX | NYSE | alphavantage | Becton Dickinson & Company |
| BDX | NYSE | fmp | Becton, Dickinson and Company |
| BDX | NYSE | alpaca | Becton, Dickinson and Co. |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Muhsin Bilal | EVP & President Connected Care | grant | 14,342 | $0.00 | $0 | 4 on EDGAR |
| Jun 26, 2026 | Feld Michael | EVP, Chief Revenue Officer | sale | 75 | $152.80 | $11,460 | 4 on EDGAR |
| Jun 24, 2026 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | sale | 1,100 | $145.66 | $160,226 | 4 on EDGAR |
| — | Sinha Manish | EVP and Chief People Officer | — | — | — | — | 3 on EDGAR |
| Jun 10, 2026 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | sale | 1,100 | $151.48 | $166,628 | 4 on EDGAR |
| Jun 1, 2026 | Menziuso Peter | EVP and President, BDI | grant | 14,258 | $0.00 | $0 | 4 on EDGAR |
| Jun 1, 2026 | Polen Thomas E Jr | Chairman, CEO and President | exercise | 20,209 | $126.16 | $2,549,567 | 4 on EDGAR |
| — | Menziuso Peter | EVP and President, BDI | — | — | — | — | 3 on EDGAR |
| May 26, 2026 | Feld Michael | EVP, Chief Revenue Officer | sale | 75 | $147.35 | $11,051 | 4 on EDGAR |
| May 8, 2026 | Byington Carrie L | Insider | grant | 105 | $149.04 | $15,649 | 4 on EDGAR |
| May 8, 2026 | Huffines Robert Luther | Insider | grant | 210 | $149.04 | $31,298 | 4 on EDGAR |
| May 7, 2026 | Roque Vitor | EVP & Chief Financial Officer | grant | 1,721 | $0.00 | $0 | 4 on EDGAR |
| Apr 27, 2026 | Feld Michael | EVP, Chief Revenue Officer | sale | 74 | $151.94 | $11,244 | 4 on EDGAR |
| Apr 6, 2026 | Neal Shana Carol | EVP and Chief People Officer | other | 1,146 | $0.00 | $0 | 4 on EDGAR |
| Mar 26, 2026 | Feld Michael | EVP, Chief Revenue Officer | sale | 75 | $156.83 | $11,762 | 4 on EDGAR |
| Mar 16, 2026 | Minnix Lanesha | EVP and General Counsel | grant | 7,492 | $0.00 | $0 | 4 on EDGAR |
| — | Minnix Lanesha | EVP and General Counsel | — | — | — | — | 3 on EDGAR |
| Mar 2, 2026 | Roque Vitor | Interim CFO | grant | 931 | $0.00 | $0 | 4 on EDGAR |
| Mar 2, 2026 | Spikner Pamela L. | SVP Controller & CAO | grant | 931 | $0.00 | $0 | 4 on EDGAR |
| Feb 4, 2026 | Jones Christopher Ian Montague | Insider | grant | 272 | $201.91 | $54,920 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query BDX context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access